AR091633A1 - Solucion inyectable de acetaminofen para su administracion por via espinal - Google Patents

Solucion inyectable de acetaminofen para su administracion por via espinal

Info

Publication number
AR091633A1
AR091633A1 ARP130102331A AR091633A1 AR 091633 A1 AR091633 A1 AR 091633A1 AR P130102331 A ARP130102331 A AR P130102331A AR 091633 A1 AR091633 A1 AR 091633A1
Authority
AR
Argentina
Prior art keywords
injectable
solution
acetaminofen
espinal
administration via
Prior art date
Application number
Other languages
English (en)
Inventor
Donati Elisabetta
Mitidieri Augusto
Caronzolo Nicola
Original Assignee
Sint Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR091633(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sint Sa filed Critical Sint Sa
Publication of AR091633A1 publication Critical patent/AR091633A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una solución acuosa inyectable de acetaminofén para el uso en el tratamiento o en la prevención del dolor mediante administración espinal, en la que dicha solución inyectable de acetaminofén está sobresaturada en una concentración comprendida entre 1.3 y 2.3% p/v. En algunas formas de realizaciones, la solución acuosa inyectable de acetaminofén se administra simultáneamente, separadamente o secuencialmente con un anestésico local por vía espinal.
ARP130102331 2012-06-29 2013-06-28 Solucion inyectable de acetaminofen para su administracion por via espinal AR091633A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001154A ITMI20121154A1 (it) 2012-06-29 2012-06-29 Soluzione iniettabile di acetaminofene per la somministrazione spinale

Publications (1)

Publication Number Publication Date
AR091633A1 true AR091633A1 (es) 2015-02-18

Family

ID=46690603

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102331 AR091633A1 (es) 2012-06-29 2013-06-28 Solucion inyectable de acetaminofen para su administracion por via espinal

Country Status (44)

Country Link
US (2) US11344517B2 (es)
EP (1) EP2874602B1 (es)
JP (1) JP5876620B2 (es)
KR (1) KR102118227B1 (es)
CN (1) CN104487051B (es)
AP (1) AP2014008152A0 (es)
AR (1) AR091633A1 (es)
AU (1) AU2013282753B2 (es)
BR (1) BR112014032818B1 (es)
CA (1) CA2876801C (es)
CL (1) CL2014003536A1 (es)
CO (1) CO7240357A2 (es)
CR (1) CR20150036A (es)
CU (1) CU20140150A7 (es)
CY (1) CY1117691T1 (es)
DK (1) DK2874602T3 (es)
DO (1) DOP2014000302A (es)
EA (1) EA028909B1 (es)
EC (1) ECSP15000500A (es)
ES (1) ES2578012T3 (es)
GE (1) GEP201706689B (es)
HR (1) HRP20160706T1 (es)
HU (1) HUE029431T2 (es)
IL (1) IL236423A (es)
IT (1) ITMI20121154A1 (es)
MA (1) MA37811B1 (es)
MD (1) MD4537C1 (es)
ME (1) ME02431B (es)
MX (1) MX369264B (es)
MY (1) MY169251A (es)
NI (1) NI201400147A (es)
NZ (1) NZ703829A (es)
PE (1) PE20150331A1 (es)
PH (1) PH12015500178B1 (es)
PL (1) PL2874602T3 (es)
PT (1) PT2874602T (es)
RS (1) RS54844B1 (es)
SG (2) SG10201704482YA (es)
SI (1) SI2874602T1 (es)
SM (1) SMT201600248B (es)
TN (1) TN2014000526A1 (es)
UA (1) UA117101C2 (es)
WO (1) WO2014002042A1 (es)
ZA (1) ZA201409478B (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023816A1 (en) * 1993-04-14 1994-10-27 Nippon Sanso Corporation Dissolved oxygen reducing apparatus
US6171298B1 (en) * 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
DE10112325A1 (de) * 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
RS53804A (en) * 2001-12-18 2006-12-15 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Parenteral composition of paracetamol
FR2851164B1 (fr) 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
DE102005037653A1 (de) * 2005-08-05 2007-02-15 Theraselect Gmbh Stabile, flüssige Formulierung von Paracetamol
AU2006346318B2 (en) * 2006-07-18 2011-02-10 Genfarma Laboratorio S.L. Injectable liquid paracetamol formulation
CN101015542A (zh) * 2007-02-13 2007-08-15 天津生机集团有限公司 家畜用复方对乙酰氨基酚注射液及其制备方法
MD3528G2 (ro) * 2007-09-28 2008-11-30 Сергей ШАНДРУ Metodă de anestezie spinală continuă la pacienţii în etate
WO2009064928A1 (en) * 2007-11-13 2009-05-22 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
EP2307056B1 (en) 2008-01-17 2021-12-15 Pharmis Biofarmacêutica, LDA Stabilized aqueous formulation containing paracetamol
WO2009143558A1 (en) 2008-05-26 2009-12-03 Silphion Pty Limited Injectable formulations
EP2243477A1 (de) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
JP2013006770A (ja) 2009-10-09 2013-01-10 Ssp Co Ltd アセトアミノフェン含有経口液剤
ES2866636T3 (es) * 2010-06-30 2021-10-19 Troikaa Pharmaceuticals Ltd Composiciones farmacéuticas que comprenden paracetamol y proceso para preparar las mismas

Also Published As

Publication number Publication date
AP2014008152A0 (en) 2014-12-31
CO7240357A2 (es) 2015-04-17
GEP201706689B (en) 2017-06-26
NZ703829A (en) 2016-06-24
MY169251A (en) 2019-03-19
MD20140138A2 (ro) 2015-06-30
ITMI20121154A1 (it) 2013-12-30
US11344517B2 (en) 2022-05-31
TN2014000526A1 (en) 2016-03-30
KR102118227B1 (ko) 2020-06-03
ES2578012T3 (es) 2016-07-20
JP5876620B2 (ja) 2016-03-02
HUE029431T2 (en) 2017-03-28
SG11201408479WA (en) 2015-01-29
CR20150036A (es) 2015-03-13
US20150148379A1 (en) 2015-05-28
AU2013282753B2 (en) 2017-03-02
CA2876801A1 (en) 2014-01-03
CY1117691T1 (el) 2017-05-17
PL2874602T3 (pl) 2016-10-31
BR112014032818B1 (pt) 2022-06-14
IL236423A0 (en) 2015-02-26
RS54844B1 (sr) 2016-10-31
MA37811B1 (fr) 2017-07-31
SI2874602T1 (sl) 2016-09-30
WO2014002042A1 (en) 2014-01-03
CN104487051B (zh) 2017-12-12
PT2874602T (pt) 2016-07-13
MA37811A1 (fr) 2016-10-31
KR20150027160A (ko) 2015-03-11
NI201400147A (es) 2015-04-13
US20160128955A1 (en) 2016-05-12
JP2015522004A (ja) 2015-08-03
MD4537B1 (ro) 2017-12-31
BR112014032818A2 (pt) 2017-06-27
EA201500065A1 (ru) 2015-10-30
SMT201600248B (it) 2016-08-31
SG10201704482YA (en) 2017-07-28
DK2874602T3 (en) 2016-07-04
ECSP15000500A (es) 2015-11-30
UA117101C2 (uk) 2018-06-25
IL236423A (en) 2017-07-31
ZA201409478B (en) 2016-01-27
ME02431B (me) 2016-09-20
EP2874602B1 (en) 2016-03-30
AU2013282753A1 (en) 2015-02-05
EA028909B1 (ru) 2018-01-31
PH12015500178A1 (en) 2015-04-06
MD4537C1 (ro) 2018-07-31
CN104487051A (zh) 2015-04-01
MX2014015402A (es) 2015-06-17
PH12015500178B1 (en) 2015-04-06
CL2014003536A1 (es) 2015-05-08
EP2874602A1 (en) 2015-05-27
MX369264B (es) 2019-11-04
CA2876801C (en) 2020-11-03
CU20140150A7 (es) 2015-10-27
DOP2014000302A (es) 2015-03-15
HRP20160706T1 (hr) 2016-08-12
PE20150331A1 (es) 2015-03-07

Similar Documents

Publication Publication Date Title
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
CL2015003634A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2013001250A1 (es) Composicion intravenosa que contiene ibuprofeno y paracetamol combinados en dosis definidas; y uso en el tratamiento del dolor y/o inflamacion.
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
CO7461127A2 (es) Código para la configuración de un dispositivo de atención al paciente
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
ECSP10010567A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
CL2011000387A1 (es) Combinacion que comprende a) 6-dimetilaminometil-1-(3-metoxifenil)-ciclohexano-1,3-diol y b) paracetamol; forma de dosificacion; uso para tratar osteoartritis y dolor.
BR112015015938A2 (pt) uso de cloridrato de fenilefrina e paracetamol, medicamento, método de tratamento de congestão das mucosas do trato respiratório superior em um humano adulto
AR091633A1 (es) Solucion inyectable de acetaminofen para su administracion por via espinal
CL2017003465A1 (es) Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria.
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
IT201700002235A1 (it) Composizione per somministrazione orale utile nel trattamento del diabete e delle sindrome metaboliche in genere
UY32985A (es) Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona
PE20160748A1 (es) Formacion de costra artificial porosa semipermeable
AR099638A1 (es) El uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmacéuticamente aceptable del mismo en la prevención y el tratamiento de la diabetes
CL2013000835A1 (es) Compuestos derivados de metilciclohexano, moduladores del oxido nitrico; composicion farmaceutica que los comprende y su uso en el tratamiento y/o profilaxis del dolor cronico o agudo.

Legal Events

Date Code Title Description
FB Suspension of granting procedure